The focus will be on 1. applications of amnion-derived mesenchymal stem cells (MSC), 2. Acute graft-vs-host-diseases (acute GVHD) experienced in transplantations, and 3. on treatments for Croh’s disease. Kaneka has implemented devices for the automatic culture of mesenchymal stem cells and devices for separating bone marrow-derived mesenchymal stem cells.
Kaneka news release, Sept.10, 2014
Kaneka enters cellular drug business